AxoGen to Participate at 99th Annual American Association of Oral and Maxillofacial Surgeons Meeting
AxoGen offers Oral and Maxillofacial surgeons solutions for the repair of peripheral nerve damage
ALACHUA, Fla., Oct. 02, 2017 (GLOBE NEWSWIRE) -- AxoGen Corporation (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve damage, today announced it will participate in the 99th Annual Meeting of the American Association of Oral and Maxillofacial Surgeons (AAOMS). The meeting, scheduled for October 9-14 at the Moscone South Convention Center in San Francisco, attracts more than 5,000 oral and maxillofacial surgeons, researchers, nurses, students, and health care professionals from all over the world to display, share and learn the advancements and innovations taking place in the field of oral and maxillofacial (OMF) surgery and dentistry.
“AxoGen’s comprehensive platform for nerve repair includes solutions to address nerve damage in the jaw resulting from either surgical injuries or reconstruction following benign tumor removal or similar procedures,” said Karen Zaderej, president and chief executive officer. “Recent clinical data has shown that timely referral to a nerve repair specialist and repair of these injuries with the AxoGen portfolio can provide meaningful recovery in up to 94 percent of these patients. We are encouraged by increased awareness of the AxoGen portfolio to assist surgeons in improving the quality of life for patients with nerve damage.”
AxoGen is supporting a Hands-On Nerve Repair Course: Numb Lip, Numb Tongue, Numb Chin and What to do When on Thursday, October 12 from 8:00 a.m. to 12 noon in Room 159. The special session will provide attendees with the opportunity to handle AxoGen products and gain a better understanding of their use in oral and maxillofacial applications.
In addition to the hands-on session, AxoGen will talk with attendees and demo products at Booth 1708 on the exhibit floor. OMF surgeon thought leaders will be available in the AxoGen booth at select times. These experts will demonstrate surgical techniques for OMF nerve repair and discuss the importance of timely referral pathways. Michael Miloro, D.M.D., M.D., FACS will be at the AxoGen booth on Thursday, October 12 from 12 noon until 1:00 p.m. John Zuniga, D.M.D., Ph.D. will be at the AxoGen booth on Friday, October 13 from 3:00-4:00 p.m.
Other conference sessions featuring AxoGen’s platform for nerve repair include Nerve Reconstruction for Patients with Medication-related Osteonecrosis of the Jaw on Friday, October 13, and Updates in Trigeminal Nerve Microsurgery on Saturday, October 14.
The American Association of Oral and Maxillofacial Surgeons (AAOMS), the professional organization representing more than 9,000 oral and maxillofacial surgeons in the United States, supports its members' ability to practice their specialty through education, research and advocacy. The mission of AAOMS is to assure excellence in patient care by promoting, protecting and advancing the specialty of oral and maxillofacial surgery, and the skill and professionalism of AAOMS members.
AxoGen (AXGN) is a global leader in innovative surgical solutions for peripheral nerve injuries. AxoGen is the only company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about restoring nerve function and quality of life to patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Damage to a peripheral nerve can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.
AxoGen's portfolio of products includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves, AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments, and Avive® Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a resorbable soft tissue covering to separate tissue layers and modulate inflammation in the surgical bed. Along with these core surgical products, AxoGen also offers AcroVal® Neurosensory & Motor Testing System and AxoTouch® Two-Point Discriminator. These evaluation and measurement tools assist health care professionals in detecting changes in sensation, assessing return of sensory, grip, and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom, and several other European and international countries.
Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "projects," "forecasts," "continue," "may," "should," "will," and variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our assessment on our internal control over financial reporting, our growth, our 2017 guidance, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
Corporate and Investor Communications
Released October 2, 2017